Nanoform Finland Oyj · OMXHEX:NANOFH
Nanoform Finland Oyj — Q3 2020 Earnings Presentation
20 slides from Nanoform Finland Oyj's earnings presentation, Nov 27, 2020
Slide 1: Nanoform Interim Report January - September 2020
Nanoform Interim Report January - September 2020 Management Presentation November 27th Nanoform is an innovative nanoparticle medicine enabling company. Nanoform works together with pharma and biotech partners globally to provide hope for patients in developing new and improved medicines utilizing N
Slide 2: Disclaimer
Disclaimer Forward-Looking Statements This presentation may contain forward-looking statements, including, without limitation, statements regarding Nanoform’s strategy, business plans and focus. The words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,”
Slide 3: Introduction to Nanoform
Introduction to Nanoform
Slide 4: The structural pharma R&D problem
The structural pharma R&D problem Only 48 drugs approved in the US last year… …while the global pharma industry R&D expenditure exceeds USD 180bn Annual number of novel drug approvals by FDA 2010-2019 Global pharmaceutical R&D spending 2010-2024E (USDbn) Chemical Biologics 60 250 213 50 17 202 207 1
Slide 5: Low bioavailability is the key issue
Low bioavailability is the key issue Poor bioavailability and low efficacy most common reasons for drug failure Majority of new drugs suffer from poor solubility Solubility Reasons for drug failure in pre-clinical trials (share of molecules) High Low 45% 40% 35% Class I1 Class II1 On market: 35% On
Slide 6: Nanoform is here to fill the gap
Nanoform is here to fill the gap The solution to low bioavailability is to decrease the particle size of the Active Pharmaceutical Ingredient (API)… Giving unsuccessful Enabling new drug candidates drugs a second chance Improving (reduce attrition) existing drugs …and Nanoform’s CESS® is the only te
Slide 7: Particle size is key
Particle size is key Smaller particle size improves a drug’s bioavailability Pre-nanoformation Post-nanoformation > Smaller particles have a larger surface area > Larger surface area of particles enables better bioavailability of a drug > Improved bioavailability implies better absorption of a drug
Slide 8: Potential benefits of CESS if commercialized and adopted
Source: Company information - Potential benefits assuming that CESS® is successfully commercialized and adopted by the pharma industry 8
Slide 9: Nanoform - Attractive revenue model
Nanoform - Attractive revenue model Predictable revenue streams through capitalizing the entire pharmaceuticals value chain Phase Proof of Concept / Proof of Process Phase I – III trials Drugs on the market Certification Non-GMP GMP GMP > Proof of concept study - assessment of the > API for clinical
Slide 10: Interim Jan-Sep 2020 update
Interim Jan-Sep 2020 update
Slide 11: 2020 Key Milestones YTD
2020 Key Milestones YTD Jan US subsidiary Nanoform USA Inc established June Nr of non-GMP production lines increased from 6 to 7 Orion signed as a repeat client to collaborate on next- July Mar West Coast US Biotech client signed generation drug development Sep Nanoform EGM elects Cynthia Schwalm as
Slide 12: Nanoform's client portfolio
Nanoform’s client portfolio Nanoform targets to achieve scale in APIs Client announced 2019 1 Global large pharma Client announced 2020 Tier 2 – Mid-sized and specialty pharma and biotech ✓ Financially stable organizations ✓ Broad pipeline of APIs in development Mid-sized and specialty pharma 2 and
Slide 13: Nanoform Q3 KPI's
Nanoform Q3 KPI’s Operational KPIs Financial KPIs EUR thousand 7-9/2020 7-9/2019 1-9/2020 1-9/2019 1-12/2019 7-9/2020 7-9/2019 1-9/2020 1-9/2019 1-12/2019 Revenue 159 501 49 Number of new projects started during the period Gross profit 101 -37 363 -182 -323 EBITDA -3,488 -1,957 -13,973 -4,445 -6,900
Slide 14: Nanoform Q3 Income Statement
Nanoform Q3 Income Statement Consolidated statement of comprehensive income 1-9/2020 comments EUR thousand 7-9/2020 7-9/2019 1-9/2020 1-9/2019 1-12/2019 > Revenue stemmed from nine PoC projects for clients (1-9/2020). Revenues are recognized over the lifetime of the projects based on hours worked. I
Slide 15: Nanoform near-term business targets for 2020 and 2021
Nanoform near-term business targets for 2020 and 2021 Topic Target Status “GMP approval expected no Achieved - GMP certificate GMP approval later than Q3 2020” awarded April 2020 ✓ “For 2020, our ambition is to Achieved – 4 new customers Ongoing client intake accelerate our growth by winning more ne
Slide 16: Nanoform mid-term business targets 2025
Nanoform mid-term business targets 2025 25 lines of >50 which Cash new APIs 5-10 are flow per year GMP positive compliant >90% ~200 gross employees margin 16
Slide 17: Nanoform launches new nanoparticle technology for Biologics
Nanoform launches new nanoparticle technology for Biologics
Slide 18: A potential game-changer in Biologics
A potential game-changer in Biologics A proprietary nanoparticle formation Nanoform near-term business target for 2021 to deliver first Biologics Proof technology to of Concept project with a pharmaceutical or biotech partner for this new deliver biological technology nanoparticles as small as 50 nm
Slide 19: Q&A
Q&A
Slide 20: Further enquiries
Further enquiries: CFO Albert Hæggström, albert.haeggstrom@nanoform.com, +358 29 370 0150 Director of Investor Relations Henri von Haartman, hvh@nanoform.com, +46 7686 650 11 Financial calendar: February 26, 2021 - Annual Review 2020. Financial Statements for financial year 2020 April 6, 2021 - Annu